Trials / Completed
CompletedNCT00427466
Pemetrexed in Patients With Soft Tissue Sarcoma
Multicenter Phase II Study With Pemetrexed in Patients With Pre-Treated Metastatic Soft Tissue Sarcomas
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-based chemotherapy and to assess the toxicity profile
Detailed description
One therapy cycle takes a total of 3 weeks. On day 1, Pemetrexed is intravenously administered. The dosage is 500 mg/m2 over a period of 10 minutes. A repetition of this procedure is performed on day 22
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-01-29
- Last updated
- 2009-02-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00427466. Inclusion in this directory is not an endorsement.